港股異動 | 美團點評再創歷史新高 南下資金熱捧
格隆匯11月4日丨美團點評(03690.HK)漲近4%,報97.5港元,股價再創歷史新高,今年以來累計漲幅約122%,成交16.7億港元,總市值5659億港元。深港通下的港股通股票名單上個月調整,美團點評獲調入,10月28日起生效。美團點評獲納入港股通後,南下資金上週連續五日淨流入美團,累計約37.98億港元。花旗上週發表報告表示,料美團點評將於11月第三週公佈第三季業績,因應用户參與度和目標津貼額度,相信公司在交易量和貨幣化方面表現勝預期。上調美團點評目標價,由88港元升至107港元,此按綜合方式作估值,評級從“買入(高風險)”升至“買入”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.